$186.57
-0.40-0.21%
近くで: -
$186.67
0.10.05%
時間外: Nov 7, 6:37 PM EDT
Comments
Loading...
アナリストの評価、目標株価、予想
Johnson & Johnson のコンセンサス目標株価は $190.18 で、22 人のアナリストの評価に基づいています。最高値は $215（10 15, 2025 に Citigroup が発表）、最安値は $150（7 23, 2024 に Daiwa Capital が発表）です。直近のアナリスト評価 3 件は Freedom Capital Markets、Citigroup、Stifel により 10 22, 2025、10 15, 2025、10 15, 2025 に発表されました。Freedom Capital Markets、Citigroup、Stifel の平均目標株価は $198.33 で、これらの最新評価から Johnson & Johnson に対して 6.25% のupsideが示唆されています。
推奨アナリスト会社1
Freedom Capital Markets
Citigroup
Stifel
Raymond James
Morgan Stanley
1アナリスト評価から算出
Johnson & Johnsonのアナリスト評価
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/22/2025 | 1.78% | Freedom Capital Markets | $180 → $190 | Downgrade | Buy → Hold | |||
10/15/2025 | 15.18% | Citigroup | $213 → $215 | Maintains | Buy | |||
10/15/2025 | 1.78% | Stifel | $165 → $190 | Maintains | Hold | |||
10/15/2025 | 11.96% | Raymond James | $174 → $209 | Maintains | Outperform | |||
10/15/2025 | 1.78% | Morgan Stanley | $178 → $190 | Maintains | Equal-Weight | |||
10/15/2025 | 9.28% | B of A Securities | $198 → $204 | Maintains | Neutral | |||
10/14/2025 | 14.64% | UBS | $190 → $214 | Maintains | Buy | |||
10/10/2025 | -4.64% | Morgan Stanley | $176 → $178 | Maintains | Equal-Weight | |||
10/09/2025 | 13.57% | Goldman Sachs | $186 → $212 | Maintains | Buy | |||
10/07/2025 | 14.11% | Citigroup | $200 → $213 | Maintains | Buy | |||
10/06/2025 | 3.39% | Bernstein | $172 → $193 | Maintains | Market Perform | |||
10/03/2025 | 6.07% | B of A Securities | $175 → $198 | Maintains | Neutral | |||
10/03/2025 | 13.57% | Wells Fargo | $170 → $212 | Upgrade | Equal-Weight → Overweight | |||
09/23/2025 | 10.36% | Guggenheim | $167 → $206 | Upgrade | Neutral → Buy | |||
09/16/2025 | 7.14% | JP Morgan | $185 → $200 | Maintains | Neutral | |||
08/21/2025 | 7.14% | Citigroup | $185 → $200 | Maintains | Buy | |||
07/17/2025 | -5.72% | Barclays | $165 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | -0.89% | RBC Capital | $181 → $185 | Maintains | Outperform | |||
07/17/2025 | -10.54% | Guggenheim | $164 → $167 | Maintains | Neutral | |||
07/17/2025 | 1.78% | UBS | $180 → $190 | Maintains | Buy | |||
07/17/2025 | -5.72% | Morgan Stanley | $171 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | -6.25% | B of A Securities | $161 → $175 | Maintains | Neutral | |||
07/10/2025 | -8.39% | Morgan Stanley | $169 → $171 | Maintains | Equal-Weight | |||
06/05/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
05/13/2025 | -18.04% | Leerink Partners | $169 → $153 | Downgrade | Outperform → Market Perform | |||
04/17/2025 | -11.61% | Barclays | $166 → $165 | Maintains | Equal-Weight | |||
04/16/2025 | -12.14% | Raymond James | $162 → $164 | Maintains | Outperform | |||
04/16/2025 | -9.47% | Morgan Stanley | $164 → $169 | Maintains | Equal-Weight | |||
04/16/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/14/2025 | -13.22% | Raymond James | $165 → $162 | Maintains | Outperform | |||
04/10/2025 | -14.82% | B of A Securities | $171 → $159 | Maintains | Neutral | |||
04/09/2025 | -12.14% | Morgan Stanley | $163 → $164 | Maintains | Equal-Weight | |||
04/09/2025 | -7.86% | Goldman Sachs | $157 → $172 | Upgrade | Neutral → Buy | |||
04/03/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/12/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/10/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/05/2025 | -8.39% | B of A Securities | $159 → $171 | Maintains | Neutral | |||
02/19/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/03/2025 | -11.07% | Guggenheim | $162 → $166 | Maintains | Neutral | |||
01/28/2025 | -11.07% | Barclays | $159 → $166 | Maintains | Equal-Weight | |||
01/23/2025 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/23/2025 | -12.68% | Morgan Stanley | $175 → $163 | Maintains | Equal-Weight | |||
01/23/2025 | -16.97% | Stifel | $170 → $155 | Maintains | Hold | |||
01/23/2025 | -9.47% | Leerink Partners | $182 → $169 | Maintains | Outperform | |||
01/23/2025 | -18.57% | Wells Fargo | $166 → $152 | Maintains | Equal-Weight | |||
01/23/2025 | -11.61% | Raymond James | $170 → $165 | Maintains | Outperform | |||
01/23/2025 | -14.82% | B of A Securities | $160 → $159 | Maintains | Neutral | |||
01/17/2025 | -14.29% | B of A Securities | $166 → $160 | Maintains | Neutral | |||
12/11/2024 | -6.25% | Citigroup | $185 → $175 | Maintains | Buy | |||
12/10/2024 | -11.07% | B of A Securities | → $166 | Reinstates | → Neutral | |||
11/15/2024 | 1.78% | Wolfe Research | → $190 | Initiates | → Outperform | |||
11/06/2024 | -13.22% | Guggenheim | $156 → $162 | Maintains | Neutral | |||
10/16/2024 | -0.89% | Citigroup | $180 → $185 | Maintains | Buy | |||
10/16/2024 | -11.07% | Wells Fargo | $163 → $166 | Maintains | Equal-Weight | |||
10/16/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/16/2024 | -3.04% | RBC Capital | $178 → $181 | Maintains | Outperform | |||
10/16/2024 | -6.25% | Morgan Stanley | $169 → $175 | Maintains | Equal-Weight | |||
10/10/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/08/2024 | -4.64% | RBC Capital | $175 → $178 | Maintains | Outperform | |||
09/30/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/23/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/20/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
09/19/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/03/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
08/05/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/23/2024 | -19.64% | Daiwa Capital | $160 → $150 | Downgrade | Outperform → Neutral | |||
07/19/2024 | -16.97% | Goldman Sachs | $160 → $155 | Maintains | Neutral | |||
07/18/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/18/2024 | -0.89% | TD Cowen | $195 → $185 | Maintains | Buy | |||
07/18/2024 | -9.47% | Morgan Stanley | $167 → $169 | Maintains | Equal-Weight | |||
07/01/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/17/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
06/04/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/22/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/16/2024 | -6.25% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/06/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/18/2024 | -8.93% | HSBC | $169 → $170 | Upgrade | Hold → Buy | |||
04/17/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/17/2024 | -10.54% | Morgan Stanley | $168 → $167 | Maintains | Equal-Weight | |||
04/17/2024 | -6.25% | RBC Capital | $181 → $175 | Maintains | Outperform | |||
04/17/2024 | -8.93% | B of A Securities | $180 → $170 | Maintains | Neutral | |||
04/15/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
03/13/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/28/2024 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/20/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/06/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | -3.04% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/24/2024 | -9.47% | Morgan Stanley | $170 → $169 | Maintains | Equal-Weight | |||
01/23/2024 | 15.18% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
01/09/2024 | 15.18% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/03/2024 | -6.25% | Raymond James | $172 → $175 | Maintains | Outperform |
よくある質問
Johnson & Johnson (JNJ) 株の目標株価はいくらですか?
Johnson & Johnsonの最新目標株価Johnson & Johnson。(NYSE:JNJ) の最新目標株価をFreedom Capital Marketsが10 22, 2025日に発表した。このアナリスト会社はJohnson & Johnson ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内（1.78% upsideの可能性あり）と予想する$190.00の目標株価を設定しました。過去1年間に53のアナリスト会社がレーティングを報告しています。
Johnson & Johnson (Johnson & Johnsonの直近のアナリスト評価は？(JNJ) の直近のアナリスト評価は？
Johnson & Johnsonの最新のアナリストレーティングはJohnson & Johnsonです。(NYSE:JNJ) の最新のアナリストレーティングはFreedom Capital Marketsによるもので、Johnson & JohnsonのJohnson & Johnsonです。{actionCompany}}のhold評価です。
Johnson & Johnson (JNJの直近のアップグレードはいつですか？(JNJ) の最後のアップグレードはいつですか？
Johnson & Johnsonの最後のアップグレードは10 3, 2025日に行われ、Wells Fargoは目標株価を$212に引き上げました。companyName}}のWells Fargoの以前のan equal-weightは$212でした。
Johnson & Johnson (Johnson & Johnsonの直近の格下げ日はいつですか？(JNJ) の最後の格下げはいつですか？
Johnson & Johnsonの最後の格下げは10 22, 2025日にFreedom Capital MarketsがJohnson & Johnsonの目標株価を$180から$190に変更した時です。
Johnson & Johnson (Johnson & Johnsonの次のアナリストレーティングはいつ発表・更新されますか？(JNJ) の次の格付けはいつですか？
アナリストは、公開財務諸表を調べたり、Johnson & Johnsonの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは10 22, 2025日に提出されましたので、次のレーティングは10 22, 2026日あたりに提出されるものと思われます。
Johnson & JohnsonのアナリストレーティングはJohnson & Johnsonですか？(JNJ) は正しいですか？
レーティングは主観的なものであり変化しますが、最新のJohnson & Johnson (JNJ) (JNJ) のレーティングは格下げで、目標株価は$180.00から$190.00でした。現在の価格 Johnson & Johnson ({{exchange}}) (JNJ) の現在の取引価格は$186.67で、これはアナリストの予測レンジwithinです。
ブラウズ アナリスト評価と目標株価 全銘柄の
こんな人も見ています
© 2025 Benzinga | All Rights Reserved